{"id":922656,"date":"2025-12-29T08:04:52","date_gmt":"2025-12-29T13:04:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/"},"modified":"2025-12-29T08:04:52","modified_gmt":"2025-12-29T13:04:52","slug":"60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/","title":{"rendered":"60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:left\">Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA<sup>\u00ae<\/sup> (<strong>tafenoquine<\/strong>) for treatment of chronic babesiosis<\/li>\n<li>Data support theory among specialists that <em>Babesia <\/em>infection may prolong recovery times in patients with chronic fatigue<\/li>\n<\/ul>\n<p>WASHINGTON, Dec.  29, 2025  (GLOBE NEWSWIRE) &#8212;  <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lRBUnXNPzxhxfMmYnSIsNs9Rcm0I0bSW9baJPsVpFCThj1r6-muN9F3ZignS-sU28IXfnQ5Vy4MHOCbmjIVjvFq01Q_URxz3e8rHu0dieMAz4CzpyWZ275OTCfVSyEMiACyQGV66-qLjxvGwh6E9_w==\" rel=\"nofollow\" target=\"_blank\"><u>60 Degrees Pharmaceuticals, Inc.<\/u><\/a>\u00a0(NASDAQ: SXTP; SXTPW) (\u201c60 Degrees Pharma\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that infection with <em>Babesia<\/em>, a parasite that causes the emerging tick-borne illness called babesiosis, was found in 24 percent of a cohort of 50 patients with chronic fatigue in a <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=woKqc2jwlhpjj3SrD2yjfLDnOGXEhnVTvoagAsF4P1ygWkr5SZ4fD0MyqNO_3L1Dh1VYia5jtIQv-88iu3ZkBZYyeeZGFabJGKLmGFr5WBM=\" rel=\"nofollow\" target=\"_blank\"><u>study<\/u><\/a> conducted by researchers at North Carolina State University, and published in <em>Pathogens<\/em>.<\/p>\n<p>Results announced today contribute to efforts to confirm a long-held theory within the U.S. vector-borne disease community that <em>Babesia<\/em> and chronic disease may be linked \u2013 specifically, that <em>Babesia<\/em> infection may prolong recovery times in patients with chronic fatigue.<\/p>\n<p>The results also reinforce the importance of the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cbpJq5dq9Rn0BfDlTss12YQDhpzwV98iCyEjD_u0Npfj329rjOKiu5srE02JsxzM17saa0veyGoHXoZ_h6SFhbW2GPUawCqtKLuL1shcwy_JF7IgKzPDxDf3TMrfqc_kOs5ESF5OejFjgYkfXZ1u_TKZ5tSc_LAogrOiomyAufuWWECMOScTbh6VTh8fY5eN6LDYTfffpdDwciqsAb37IXwOIDwiGz1eEGtlruwimAd-mUEivRUETaxqFAC22rXs\" rel=\"nofollow\" target=\"_blank\"><u>B-Free Chronic Babesiosis Study<\/u><\/a> (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GxjEbaPT_41Fq4e05I44eUvxqAWykfurtsSJlMfZYZ7s30nvOXADuynXjIdvIbRdIB1bVWrqw4xKO7FdGNHmc6G8HacgQbSseT2UvbgZw0SrixC9Tx7Ys7rMh7qct1u9llERSkdh1SLZZqiuedcIHmY3kP2N0TLTZP3STegEzc8M5CBlWMlD--NAQRGkand_nJrrej3Ng4jZd8nb8Az6WxiOXM25CryRHbQXA0AGmyfUGOqmTHObTZmGEZICxqgMjBxl3ehBr4snh0yxNRXRlHAEhU78-ypP5VUGNe0dVVYtDLTL_TID8Od0C8XVuVdkApOrivAawyF8B3AZHVWeHVevsjqDlF-8BXw9-Xs9-NsoMeFzBP93UeX_Zy1GmzaNOIQK5bKIBkK_X3F8qWtxxYipXGO76Nnh1PcOmzdfkOM=\" rel=\"nofollow\" target=\"_blank\"><u>NCT06656351<\/u><\/a>), which is evaluating efficacy and safety of the ARAKODA\u00a0regimen of\u00a0<strong>tafenoquine<\/strong>\u00a0over 90 days for resolution of severe fatigue in patients with chronic babesiosis. The Company\u2019s B-Free Study is now enrolling at the Icahn School of Medicine at Mount Sinai in New York.<\/p>\n<p>\u201cHealthcare providers who treat tick-borne illness may not be surprised by the results of this study,\u201d said 60 Degrees Pharma Chief Executive Officer,\u00a0Geoffrey Dow. \u201cWhile the results don\u2019t prove that <em>Babesia<\/em> infection causes chronic disease, they are consistent with that hypothesis and highlight the need for prospective controlled studies which the Company is now undertaking.\u201d<\/p>\n<p>\n        <strong>Tafenoquine<\/strong>\u00a0is approved for malaria prophylaxis in\u00a0the United States\u00a0under the product name ARAKODA<sup>\u00ae<\/sup>.\u00a0<strong>Tafenoquine<\/strong>\u00a0has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the\u00a0United States Food and Drug Administration\u00a0for such an indication.<\/p>\n<p>\n        <strong>About the North Carolina State University Chronic Fatigue Study<\/strong>\n      <\/p>\n<p>The study involved a cohort of 50 participants selected from a group of 173 individuals who self-reported a history of chronic diseases and potential exposure to arthropod vectors. Participants had all experienced fatigue for at least six months with concurrent neurological symptoms. Participants provided three blood samples over a week, which were archived and later cultured and tested for <em>Babesia<\/em> DNA using PCR assays.<\/p>\n<p>The study was conducted under an Institutional Review Board (IRB)-approved protocol and was funded in part by 60 Degrees Pharma.<\/p>\n<p>\n        <strong>About Babesiosis<\/strong><br \/>\n        <br \/>Babesiosis is a tick-borne illness caused by\u00a0<em>Babesia<\/em>\u00a0parasites that develop and multiply in red blood cells. Its symptoms include fevers, chills, sweats, and fatigue, and in severe cases, can be life-threatening in elderly and immunosuppressed patients. Incidence of the disease is rapidly rising, particularly in the Northeast. Transmitted through the bite of the black-legged (deer) tick, the vector that spreads Lyme disease, babesiosis is an orphan disease.\u00a0Insurance claims research commissioned by the Company suggest that the minimum annual incidence of babesiosis is at least 25,000 cases per year, although the true number may be much larger than this. Currently no U.S. Food and Drug Administration (FDA)-approved treatment exists specifically for babesiosis.<\/p>\n<p>\n        <em>Babesia<\/em>\u00a0infection persists for months, and potentially for several years, following a tick bite. In patients with risk factors (e.g., immunosuppression, age, asplenia), persistent infection may result in recurring clinical relapses of the disease, each with the potential for hospitalization. In individuals without such known risk factors, it has been generally assumed that persistent infection is not clinically meaningful. However, the potential clinical significance of persistent infection in individuals with dysregulated immune systems (e.g., chronic tick-borne diseases, long Covid and other long syndromes) has not been studied, but is hypothesized to complicate recovery from other chronic symptoms. The lack of sufficiently sensitive, FDA-approved diagnostics has stymied efforts to study this problem.<\/p>\n<p>\n        <strong>About\u00a060 Degrees Pharmaceuticals, Inc.<\/strong><br \/>\n        <br \/>60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved\u00a0U.S. Food and Drug Administration\u00a0approval of Its lead product, ARAKODA<sup>\u00ae<\/sup>\u00a0(<strong>tafenoquine<\/strong>), for malaria prevention in 2018. ARAKODA is commercially available in the\u00a0U.S.\u00a0and\u00a0Australia.\u00a060 Degrees Pharmaceuticals, Inc.\u00a0also collaborates with prominent research and academic organizations in the\u00a0U.S.\u00a0and\u00a0Australia.\u00a060 Degrees Pharmaceuticals, Inc.\u00a0is headquartered in\u00a0Washington, D.C., with a subsidiary in\u00a0Australia. Learn more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=U5YNVAIwLn3eB7u6jhymz1ut4CQjCLgo9U4SQUn7VPFoHN1qQ570ZhSJ6Jsvai1OaqoP5DzMcMvLXtyzsdQYzLDWJkm-mESv-Te30YWEZLEhcymgQbHKmDOqfFS1irgd\" rel=\"nofollow\" target=\"_blank\"><u>www.60degreespharma.com<\/u><\/a>.<\/p>\n<p>The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management\u2019s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release may contain \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the\u00a0U.S.\u00a0Private Securities Litigation Reform Act of 1995. Forward\u2010looking statements reflect the current view about future events. When used in this press release, the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cfuture,\u201d \u201cintend,\u201d \u201cplan,\u201d or the negative of these terms and similar expressions, as they relate to us or our management, identify forward\u2010looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs,\u00a0expectations\u00a0and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for\u00a0<strong>tafenoquine<\/strong>\u00a0(ARAKODA<sup>\u00ae<\/sup> or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market.\u00a0More detailed information about the Company and the risk factors that may affect the realization of forward- looking statements is set forth in the Company\u2019s filings with the\u00a0Securities and Exchange Commission\u00a0(\u201cSEC\u201d), including the information contained in our Annual Report on Form 10-K filed with the\u00a0SEC\u00a0on\u00a0April 1, 2024, and our subsequent\u00a0SEC\u00a0filings. Investors and security holders are urged to read these documents free of charge on the SEC\u2019s website at\u00a0www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company\u2019s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.<\/p>\n<p>Media Contact:<br \/>Sheila A. Burke<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4WFDCEmQkukLnDgos8um6tJU0ruGTt2OsgL8-qh4dI5SzuV7tCi_yIHhX-pOaDx6LbrnhaXZOXwQQP7uRLkRjak9kvSVmF_5YwvLjXEFeg1bztrLthISGQxNs9fAVI7mFnvqE6YYYqbV-BA4CypOU5f0d3-bLvJe1XGn5A1_Lco=\" rel=\"nofollow\" target=\"_blank\"><u>SheilaBurke-consultant@60degreespharma.com<\/u><\/a><br \/>(484) 667-6330<\/p>\n<p>Investor Contact:<br \/>Patrick Gaynes<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iP29sMWJDgHN0jgBHLOd8qs4JImtHjrl4gM0Ms1cuLshtX6S80a0P-JeMlCSHOqyYQlH84xHeRV_CMYhrezJL2UA_Mcr_et8jsajM9tA36WHD2JaBOCWupkdn2t9GlZsZe0-3O_O1S8CRraxkj9ZJQ==\" rel=\"nofollow\" target=\"_blank\"><u>patrickgaynes@60degreespharma.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzQwNSM3MzM2OTM5IzIxODIzMzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2RlMGJiZTQtY2MzYi00YjVkLTkwYzgtNGI4ZTkxZTRhNzBmLTExOTM5MDctMjAyNS0xMi0yOS1lbg==\/tiny\/Sixty-Degrees-Pharmaceuticals.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA\u00ae (tafenoquine) for treatment of chronic babesiosis Data support theory among specialists that Babesia infection may prolong recovery times in patients with chronic fatigue WASHINGTON, Dec. 29, 2025 (GLOBE NEWSWIRE) &#8212; 60 Degrees Pharmaceuticals, Inc.\u00a0(NASDAQ: SXTP; SXTPW) (\u201c60 Degrees Pharma\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that infection with Babesia, a parasite that causes the emerging tick-borne illness called babesiosis, was found in 24 percent of a cohort of 50 patients with chronic fatigue in a study conducted by researchers at North Carolina State University, and published in Pathogens. Results announced today contribute to efforts to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-922656","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA\u00ae (tafenoquine) for treatment of chronic babesiosis Data support theory among specialists that Babesia infection may prolong recovery times in patients with chronic fatigue WASHINGTON, Dec. 29, 2025 (GLOBE NEWSWIRE) &#8212; 60 Degrees Pharmaceuticals, Inc.\u00a0(NASDAQ: SXTP; SXTPW) (\u201c60 Degrees Pharma\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that infection with Babesia, a parasite that causes the emerging tick-borne illness called babesiosis, was found in 24 percent of a cohort of 50 patients with chronic fatigue in a study conducted by researchers at North Carolina State University, and published in Pathogens. Results announced today contribute to efforts to &hellip; Continue reading &quot;60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-29T13:04:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzQwNSM3MzM2OTM5IzIxODIzMzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State\",\"datePublished\":\"2025-12-29T13:04:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\\\/\"},\"wordCount\":1309,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNzQwNSM3MzM2OTM5IzIxODIzMzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\\\/\",\"name\":\"60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNzQwNSM3MzM2OTM5IzIxODIzMzg=\",\"datePublished\":\"2025-12-29T13:04:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNzQwNSM3MzM2OTM5IzIxODIzMzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNzQwNSM3MzM2OTM5IzIxODIzMzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/","og_locale":"en_US","og_type":"article","og_title":"60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State - Market Newsdesk","og_description":"Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA\u00ae (tafenoquine) for treatment of chronic babesiosis Data support theory among specialists that Babesia infection may prolong recovery times in patients with chronic fatigue WASHINGTON, Dec. 29, 2025 (GLOBE NEWSWIRE) &#8212; 60 Degrees Pharmaceuticals, Inc.\u00a0(NASDAQ: SXTP; SXTPW) (\u201c60 Degrees Pharma\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that infection with Babesia, a parasite that causes the emerging tick-borne illness called babesiosis, was found in 24 percent of a cohort of 50 patients with chronic fatigue in a study conducted by researchers at North Carolina State University, and published in Pathogens. Results announced today contribute to efforts to &hellip; Continue reading \"60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-29T13:04:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzQwNSM3MzM2OTM5IzIxODIzMzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State","datePublished":"2025-12-29T13:04:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/"},"wordCount":1309,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzQwNSM3MzM2OTM5IzIxODIzMzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/","name":"60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzQwNSM3MzM2OTM5IzIxODIzMzg=","datePublished":"2025-12-29T13:04:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzQwNSM3MzM2OTM5IzIxODIzMzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzQwNSM3MzM2OTM5IzIxODIzMzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-detection-of-babesia-infection-in-24-percent-of-patients-presenting-with-chronic-fatigue-in-peer-reviewed-sponsored-study-at-nc-state\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/922656","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=922656"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/922656\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=922656"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=922656"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=922656"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}